IACH Journal Club

IACH Journal Club – Video Library

The scientific and medical literature is growing very rapidly. However, a critical evaluation and appraisal of the available information is needed. No physician is able “to digest” in a timely manner, the huge amount of knowledge being generated every day.
There is also a need to expand and balance each physician’s scope of what is happening in the world of clinical research while informing patients’ care and research directions. Scientific and medical collaboration which is crucial for good clinical practice and state of the art patient care. But what does “collaboration” really mean? (e.g. doctors sitting, talking, and exchanging ideas that push toward the goal of creating better health care, optimizing therapies, etc.) One way is through a JOURNAL CLUB!

The IACH journal club is a regular gathering of physicians and scientists to discuss a recent research paper published in a peer-reviewed journal. The goal is to present a summary of the chosen paper as proposed by the steering committee within the most recent hematology literature. Then, the discussion begins between the moderator, the panelist(s) and the audience. The goal is to initiate more discussion about a given topic, and how the results relate to the current knowledge, and at the end generate a healthy debate on the impact of the results on clinical practice.

Momelotinib Versus Danazol in Symptomatic Patients with Anaemia and Myelofibrosis (MOMENTUM)
Dr. Remy Dulery, Prof. Ruben Mesa
March 21, 2023

Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
Dr. Doris Hansen, Dr. Roni Shouval
Feb. 21, 2023

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Prof. Arnold Ganser, Dr. Daver Naval
Feb. 7, 2023

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis
Prof. Ali Bazarbachi, Dr. Roberta Di Blasi
January 24, 2023

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7)
Dr. Elias Mai, Dr. Bruno Paiva
December 6, 2022

A prospective, randomized trial of patient-reported outcome measures to drive management decisions in hematology and oncology
Cynthia Chmielewski, Dr. Kumar, Prof. Nagler
November 22, 2022

Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials
Dr. Zinaida Perić, Dr. DeFilipp Zachariah
October 25, 2022

Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia
Prof. Thomas Cluzeau, Prof. Guillermao Garcia Manero, Prof. Amer Zeidan
October 11, 2022

Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm
Prof. Naveen Pemmaraju, Prof. Alexandros Spyridonidis
September 20, 2022

Role of CD19 CAR T Cells in Second Line Large B Cell Lymphoma
Miguel Perales, Saad S. Kenderian, Olalekan O. Oluwole, Mehdi Hamadani, Anna Sureda, Arnon Nagler,
July 19, 2022

Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma
Prof. Jean luc Harousseau, Prof. Bruno Paiva
June 28, 2022

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
Prof. Graham Jackson, Prof. Francesca Gay
May 17, 2022

Gut microbiome correlates of response and toxicity following anti CD19 CAR T cell therapy
Prof. Melody Smith, Prof. Florent Malard
April 21, 2022

The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT
Prof. Roni Shouval, Prof. Nicola Polverelli
March 29, 2022

Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy
Prof. Ibrahim Yakoub-Agha, Prof. Naveen Pemmaraju
Mar. 8, 2022

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
Prof. Luciano J. Costa, Prof. Francesca Gay
Feb. 8, 2022

Polatuzumab Vedotin in PreviouslyUntreated Diffuse Large B-Cell Lymphoma
Prof. Hervé TILLY, Prof. Ali Bazarbachi
Jan. 25, 2022

Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor–Free Chronic Graft- Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies
Prof. Miguel-Angel Perales, Prof. Didier Blaise
Jan. 4, 2022

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Prof. Thierry Facon and Prof. Mchel Delforge
Nov. 23, 2021

IACH Journal Club: Autologous Transplant versus Chimeric Antigen Receptor T-cell Therapy for Relapsed DLBCL in Partial Remission
Prof. Anna Sureda and Prof. Mehdi Hamadani
October 18, 2021

IACH Journal Club: CD19 Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
Prof. Raffaella Greco and Prof. Andrea Bacigalupo
October 6, 2021

IACH Journal Club: Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
Prof. Nizar J. Bahlis, Dr Cyrille Touzeau
September 21, 2021

IACH Journal Club: HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis
Prof. Mary Eapen, Prof. Arnon Nagler
September 7, 2021

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
Dr. Shambavi Richard, Dr. Salomon Mainer
July 20, 2021

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia
Prof. Stephen A. Strickland, Prof. Thomas Cluzeau
July 6, 2021

ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease
Alex Lazaryan, Prof. Bipin Savani
June 24, 2021

Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation
Dr. Amanda Olson, Dr. Annalisa Ruggeri
June 8, 2021

Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma
Prof. Graham Jackson, Prof. Jean luc Harousseau
May 25, 2021

Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS)
Prof. Elie Azoulay, Prof. Olalekan Oluwole
May 11, 2021

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
Prof. Anna Sureda, Dr. Reid Merryman
April 26, 2021

Identification of bacteria-derived HLA-bound peptides in melanoma
Dr. Adi Nagler, Prof. Martin Larsen
April 13, 2021

Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study
Dr. Jonathan Peled, Dr. Florent Malard
March 30, 2021

Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase 3 Study
Prof. Peter Bader, Prof. Arnon Nagler
March 9, 2021

Evaluation of Sustained MRD Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR
Dr. Nizar Bahlis and Dr. Salomon Manier
February 9, 2021

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
Prof. Pau Montesinos and Prof. Thomas Prebet
January 26, 2021

Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma
Prof. Marcelo C. Pasquini and Prof. Christian Chabannon
December 3rd, 2020

Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group
Prof. Steven Le Gouill and Prof. Christian Gisselbrecht
November 19, 2020

Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
Prof. Robin Foà and Dr. Eolia Brissot
November 2, 2020

The Phase III TOURMALINE MM4 Trial
Prof. María-Victoria Mateos and Prof. Karthik Ramasamy
October 20, 2020

Introduction of the IACH Journal Club
Prof. Mohamad Mohty
October 15, 2020

The Journal Club Meetings are supported in part by an unrestricted grant provided by the following supporters: